Uncategorized

Discurriendo por la resbaladiza frontera entre los robots enriquecidos con material biológico y los cíborgs, la labor de diversos equipos de científicos en el mundo avanza más rápidamente de lo que lo hacen los juicios morales y la legislación.   El e …

En este Short examinamos el curioso acto de desperezarse y sus posibles orígenes y efectos.     …

Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ will collectively present four studies across 14 tumor types at the 2023 American Association for Cancer Research Annual Meeting being held April 14-19, 2023 in Orlando, Florida, at Booth Number 130.

Immunis, Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has appointed Neil Sahota as its Chief Artificial Intelligence Officer.

Bio-Thera Solutions, Ltd. announced the company will present one poster concerning Phase 1 clinical results for BAT1006 at the 2023 American Association for Cancer Research Annual Meeting taking place April 14 – April 19, 2023 in Orlando, Florida.

QIAGEN announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other diseases to turn cell-free DNA liquid-biopsy samples into libraries ready for next-generation sequencing in less than eight hours.

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapies announces a poster presentation at AACR 2023 of an independent analysis undertaken by AstraZeneca, on data from ImaginAb’s IAB-CD8-201 ‘iCorrelate’ Phase II study.

OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced two poster presentations highlighting new preclinical data from its oxMIF-targeting drug candidate pipeline at the upcoming American Association for Cancer Research Annual Meeting 2023, held from April 14-19, in Orlando, Florida.

SystImmune, Inc has announced that it will present data from seven preclinical programs in poster presentations at the American Association of Cancer Research meeting, which will be held in Orlando, FL, from April 14th to 19th, 2023.

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.